Original ResearchFull Report: Clinical—Alimentary TractAssociation Between Helicobacter pylori Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis
Keywords
Abbreviations used in this paper
Cited by (0)
This article has an accompanying continuing medical education activity on page e14. Learning Objective: Upon completion of this examination, successful learners will be able to: (1) estimate the benefit of Helicobacter pylori eradication on gastric cancer risk; (2) list factors that modify the effect of H pylori eradication on gastric cancer risk; (3) describe the risk reduction in gastric cancer associated with H pylori eradication.
Conflicts of interest These authors disclose the following: Dr Graham is a consultant for RedHill Biopharma regarding novel Helicobacter pylori therapies and has received research support for culture of H pylori. He is a consultant for Otsuka Pharmaceuticals regarding diagnostic breath testing and for BioGaia in relation to probiotic therapy for H pylori infection. The remaining authors disclose no conflicts.
Funding This study was supported by the Health Promotion Administration, Ministry of Health and Welfare (MOHW103-TDU-212-114009), National Taiwan University Hospital (104-P01), and National Research Program for Biopharmaceuticals (104-2325-B-002-029). The funding source had no role in study design, data collection, analysis or interpretation, report writing, or the decision to submit this paper for publication.
Author names in bold designate shared co-first authorship.
- ∗
Authors share co-first authorship.